|Systematic (IUPAC) name|
Magnesium aluminate monohydrate
|Excretion||Fecal and renal|
|CAS Registry Number|
A02 (combination with antiflatulents)
|Molecular mass||212.66 g/mol|
|(what is this?)|
Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.
Interactions and adverse reactions
Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.
The drug is sold with the following brand names:Maganta plus (Square pharma,Bangladesh), Digecid Plus (Beximco Pharma, Bangladesh), Marlox Plus (Incepta pharma Bangladesh), Gastid (SK+F, Bangladesh), Novelta (Bangladesh), Gadral (Italy); Magaltop (Italy); Magralibi (Italy); Mylanta (Australia); Riopan (Argentina, Austria, Brazil, Egypt, Germany, Italy, Mexico, Belgium, Switzerland, Greece).
|This article needs additional citations for verification. (September 2014)|
- Laurence L., Brunton. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|